Join Growin Stock Community!

Lantheus holdings, inc.LNTH.US Overview

US StockHealthcare
(No presentation for LNTH)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LNTH AI Insights

LNTH Overall Performance

LNTH AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LNTH Recent Performance

2.46%

Lantheus holdings, inc.

0.05%

Avg of Sector

-0.31%

S&P500

LNTH PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LNTH Key Information

LNTH Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LNTH Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Price of LNTH

LNTH FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LNTH Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.43
PE Ratio (TTM)
31.08
Forward PE
10.26
PS Ratio (TTM)
3.30
PB Ratio
4.44
Price-to-FCF
14.65
METRIC
VALUE
vs. INDUSTRY
Gross Margin
61.10%
Net Margin
15.15%
Revenue Growth (YoY)
0.50%
Profit Growth (YoY)
-4.69%
3-Year Revenue Growth
15.62%
3-Year Profit Growth
12.95%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.43
PE Ratio (TTM)
31.08
Forward PE
10.26
PS Ratio (TTM)
3.30
PB Ratio
4.44
Price-to-FCF
14.65
Gross Margin
61.10%
Net Margin
15.15%
Revenue Growth (YoY)
0.50%
Profit Growth (YoY)
-4.69%
3-Year Revenue Growth
15.62%
3-Year Profit Growth
12.95%

  • When is LNTH's latest earnings report released?

    The most recent financial report for Lantheus holdings, inc. (LNTH) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LNTH's short-term business performance and financial health. For the latest updates on LNTH's earnings releases, visit this page regularly.

  • Where does LNTH fall in the P/E River chart?

    According to historical valuation range analysis, Lantheus holdings, inc. (LNTH)'s current price-to-earnings (P/E) ratio is 20.87, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of LNTH?

    According to the latest financial report, Lantheus holdings, inc. (LNTH) reported an Operating Profit of 77.18M with an Operating Margin of 18.97% this period, representing a decline of 32.22% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is LNTH's revenue growth?

    In the latest financial report, Lantheus holdings, inc. (LNTH) announced revenue of 406.79M, with a Year-Over-Year growth rate of 4.01%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does LNTH have?

    As of the end of the reporting period, Lantheus holdings, inc. (LNTH) had total debt of 569.42M, with a debt ratio of 0.26. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does LNTH have?

    At the end of the period, Lantheus holdings, inc. (LNTH) held Total Cash and Cash Equivalents of 359.12M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does LNTH go with three margins increasing?

    In the latest report, Lantheus holdings, inc. (LNTH) achieved the “three margins increasing” benchmark, with a gross margin of 59.2%%, operating margin of 18.97%%, and net margin of 13.3%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess LNTH's profit trajectory and future growth potential.

  • Is LNTH's EPS continuing to grow?

    According to the past four quarterly reports, Lantheus holdings, inc. (LNTH)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.83. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LNTH?

    Lantheus holdings, inc. (LNTH)'s Free Cash Flow (FCF) for the period is 81.39M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 38.97% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.